Combined Use of BIOTRONIK Home Monitoring and Predefined Anticoagulation to Reduce Stroke Risk
Status:
Terminated
Trial end date:
2013-06-01
Target enrollment:
Participant gender:
Summary
The IMPACT Study will investigate the potential clinical benefit of the combined use of
BIOTRONIK Home Monitoring (HM) technology and a predefined anticoagulation plan compared to
conventional device evaluation and physician-directed anticoagulation in patients with
implanted dual-chamber defibrillators or cardiac resynchronization therapy devices.